The Patent Finder

Roche Palo Alto LLC

50 patents currently held · Updated Nov 21, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

49
Ending by 2030
Nov 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 7, 2027
    The maintenance fee for Isoxazolo-Pyridine Derivatives (US 9,073,908) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
  • 1 fee due May 3, 2027
    The maintenance fee for Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists (US 9,173,861) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,491,821Inhibitors of P2X3
In force
 · USPTO record
In forceUSPTO record
US 8,349,572Stable cell lines expressing hERG
In force
 · USPTO record
In forceUSPTO record
US 7,625,949Methods for treating retroviral infections
In force
 · USPTO record
In forceUSPTO record
US 7,595,405Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
In force
 · USPTO record
In forceUSPTO record
US 8,193,368Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
In force
 · USPTO record
In forceUSPTO record
US 10,201,525Tetrazole-Substituted Arylamides as PX2 and PX2/3 Antagonists
In force
 · Low confidence
In forceLow confidence
US 7,776,590Stable cell lines expressing hERG
In force
 · USPTO record
In forceUSPTO record
US 7,858,632Diaminopyrimidines as P2X3 and P2X2/3 Antagonists
In force
 · High confidence
In forceHigh confidence
US 8,580,960Process for synthesis of phenoxy diaminopyrimidine derivatives
In force
 · USPTO record
In forceUSPTO record
US 9,643,934Process for synthesis of phenoxy diaminopyrimidine derivatives
In force
 · USPTO record
In forceUSPTO record
10 of 50 patents shown.
Pro members see all 50.
Pro members: see all 50 patents
Also on record, not counted in the 50: 3 patents in force now held by others · 258 lapsed for an unpaid fee · 69 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 17 abandoned · 58 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited